银屑病关节炎复合疾病活动度指标比较:基于古塞奇尤单抗II期试验的效能评估
该II期试验将活动性银屑病关节炎患者按2:1随机分配至古塞奇尤单抗100mg组(n=100)或安慰剂组(n=49),评估PASDAS、GRACE、mCPDAI和DAPSA四种复合指标。第24周时,古塞奇尤单抗组各指标均显著改善,且达到低/极低/缓解状态的患者比例显著高于安慰剂组;PASDAS和GRACE在检测治疗效应上比mCPDAI和DAPSA更敏感。
要点
- 古塞奇尤单抗在第24周显著改善PASDAS、GRACE、mCPDAI和DAPSA评分。
- 古塞奇尤单抗组达到低/极低/缓解状态的比例显著高于安慰剂组。
- PASDAS和GRACE检测治疗效应的敏感性优于mCPDAI和DAPSA。
核心结论
- 古塞奇尤单抗在基于所有评估的PsA复合指标上均能有效达到低疾病活动度/缓解。
- PsA临床试验和临床中复合指标的使用需仔细考虑以优化可行性和工具性能。
研究设计与样本
- II期试验,活动性PsA患者随机2:1接受古塞奇尤单抗100mg(n=100)或安慰剂(n=49),第0、4周及之后每8周皮下给药至第44周。
- 第16周肿胀和压痛关节改善<5%者可早期 escape 至开放标签乌司奴单抗;安慰剂组在第24、28、36、44周交叉接受古塞奇尤单抗100mg。
主要发现
- 第24周时,古塞奇尤单抗组PASDAS、GRACE、mCPDAI和DAPSA的平均变化分别为-2.50、-2.73、-3.8和-23.08,安慰剂组分别为-0.49、0.35、-0.8和-4.98(所有P < 0.001)。
- 古塞奇尤单抗组达到PASDAS极低+低疾病活动度的比例为35% vs 安慰剂4%(P < 0.001)。
- 古塞奇尤单抗组达到GRACE低/极低/缓解的比例为30% vs 安慰剂2%(P < 0.001)。
- 古塞奇尤单抗组达到mCPDAI低/极低/缓解的比例为46% vs 安慰剂10%(P < 0.001)。
- 古塞奇尤单抗组达到DAPSA缓解+低疾病活动度的比例为40% vs 安慰剂12%(P < 0.001);DAPSA缓解率为12% vs 安慰剂0%(P < 0.01)。
关键数值与推荐
- PASDAS和GRACE在检测治疗效应上比mCPDAI和DAPSA更敏感。
- 达到DAPSA低疾病活动度的患者中,残留皮肤疾病和附着点炎较其他指标低疾病活动度患者略更突出。
临床怎么用
- 临床中选择PsA复合指标时需权衡可行性与工具性能,PASDAS和GRACE可能更敏感地反映治疗效应。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess performance of psoriatic arthritis (PsA) composite indices and evaluate guselkumab's effect on achieving low disease activity or remission. METHODS: In this phase II trial, patients with active PsA (≥3 tender and ≥3 swollen joints, C-reactive protein level ≥0.3 mg/dl, ≥3% body surface-area with psoriasis involvement) were randomized 2:1 to subcutaneous guselkumab 100 mg (n = 100) or placebo (n = 49) at week 0, week 4, and every 8 weeks through week 44. At week 16, patients with <5% improvement in swollen and tender joints could early escape to open-label ustekinumab. Patients continuing placebo crossed over to receive guselkumab 100 mg at weeks 24, 28, 36, and 44 (placebo to guselkumab). PsA composite indices (Psoriatic Arthritis Disease Activity Score [PASDAS], Group for Research and Assessment of Psoriasis and Psoriatic Arthritis composite score [GRACE], modified Composite Psoriatic Disease Activity Index [mCPDAI], and Disease Activity in Psoriatic Arthritis [DAPSA]) were analyzed as secondary outcomes (last observation carried forward for missing/post-early escape data through week 24; observed data post-week 24). Instrument performance was assessed. RESULTS: Baseline PASDAS, GRACE, mCPDAI, and DAPSA scores indicated moderate-to-high disease activity. At week 24, mean changes in each of these composite indices showed significant improvement with guselkumab (-2.50, -2.73, -3.8, and -23.08, respectively) versus placebo (-0.49, 0.35, -0.8, and -4.98, respectively; P < 0.001 for all). Significantly more guselkumab-treated patients achieved low/very low/remitted disease activity states according to PASDAS (very low + low 35% versus 4%; P < 0.001), GRACE (30% versus 2%; P < 0.001), mCPDAI (46% versus 10%; P < 0.001), and DAPSA (remission + low 40% versus 12%; P < 0.001). A total of 12% of guselkumab-treated versus no placebo-treated patients achieved DAPSA remission (P < 0.01). The PASDAS and GRACE instruments were more sensitive than the mCPDAI and DAPSA tools in detecting treatment effect. Residual skin disease and enthesitis were marginally more prominent in patients achieving DAPSA low disease activity versus other indices. CONCLUSION: Guselkumab demonstrated efficacy in achieving low disease activity/remission based on all PsA composite indices assessed. Composite index use in PsA trials and the clinic requires careful consideration to optimize feasibility and instrument performance.
引用
- Helliwell PS, Deodhar A, Gottlieb AB, et al. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. Arthritis Care Res (Hoboken). 2020. PMID: 31421033. doi:10.1002/acr.24046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。